Date:9/24/2010

predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statement
'/>"/>

SOURCE Tarsa Therapeutics, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
2. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
3. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
4. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
5. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
8. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
9. Trius Therapeutics Reports 2010 Second Quarter Results
10. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
11. MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute